# Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma requires prompt tissue-confirmed classification, molecular risk assessment, stage-directed curative-intent therapy, and early referral for cellular therapy when relapse occurs within 12 months or disease is refractory.

**Clinical question:** How should physicians classify, treat, and sequence therapy for newly diagnosed and relapsed diffuse large B-cell lymphoma?

Updated: 2026-08-21T02:12:47.518334+00:00

## What matters in practice
- Establish DLBCL only when biopsy shows clearly delineated sheets of large B cells; do not assign the diagnosis from limited clinical or imaging findings alone. [6]
- Obtain MYC, BCL2, and BCL6 rearrangement testing as part of standard DLBCL workup because concurrent MYC and BCL2 and/or BCL6 rearrangements identify a biologically high-risk group. [11][21]
- For previously untreated DLBCL with IPI 2-5, pola-R-CHP improved persistence of remission versus R-CHOP without a significant overall-survival difference in POLARIX. [4]
- Relapsed or refractory disease within 12 months of first-line therapy should trigger early CAR T-cell therapy evaluation; axicabtagene ciloleucel and lisocabtagene maraleucel are used in this setting. [21]
- After at least two systemic lines, CD20×CD3 bispecific antibodies provide an outpatient-accessible option, particularly after or when ineligible for CAR T-cell therapy; CRS prevention and monitoring are integral to delivery. [19][20]

## Confirm DLBCL and identify pathologic mimics before treatment

A diagnostic delay is preferable to treating an incorrectly classified aggressive B-cell neoplasm.

Obtain an excisional lymph-node biopsy when feasible, or a sufficiently large core biopsy from the most metabolically active and accessible lesion. The diagnosis of DLBCL should be made only when pathology identifies clearly delineated sheets of large B cells. [6]

Request integrated hematopathology review with B-cell immunophenotyping and assessment of CD10, BCL6, MUM1/IRF4, BCL2, MYC, CD5, cyclin D1, and CD23 when morphology or phenotype raises an alternative mature B-cell neoplasm. CD10, BCL6, MUM1/IRF4, BCL2, and MYC expression patterns help distinguish DLBCL from mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, and other aggressive B-cell lymphomas, but immunophenotype alone does not establish the genetic high-grade category. [22]

Specifically determine whether the presentation is de novo DLBCL or histologic transformation from an indolent B-cell lymphoma. Richter transformation represents conversion, usually to DLBCL, in patients with chronic lymphocytic leukemia; DLBCL can also arise through transformation of follicular lymphoma. A documented antecedent indolent lymphoma changes prognostic framing and should prompt review of prior pathology and treatment exposure. [1][9]
- Do not label MYC/BCL2 protein coexpression as double-hit lymphoma. MYC and BCL2 coexpression by immunohistochemistry carries adverse prognosis even without concurrent gene translocations, but rearrangement status requires cytogenetic testing. [10]
- If morphology is intermediate between DLBCL and Burkitt lymphoma, or clinical behavior is highly proliferative with elevated LDH, marrow involvement, and rapid progression, expand the evaluation for high-grade B-cell lymphoma rather than defaulting to DLBCL, not otherwise specified. [22]

*Pathology findings that change DLBCL classification or the next diagnostic action. [6][10][11][22]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Clearly delineated sheets of large B cells | Required morphologic basis for DLBCL diagnosis. [6] | Proceed with integrated immunophenotypic and cytogenetic characterization. [6][11] |
| MYC and BCL2 protein coexpression | Adverse prognostic feature; it does not prove MYC and BCL2 rearrangements. [10] | Perform or confirm FISH-based rearrangement testing. [10][11] |
| MYC rearrangement plus BCL2 and/or BCL6 rearrangement | Double-hit or triple-hit biology associated with poor outcomes after standard chemotherapy. [21] | Document high-risk biology before finalizing the initial treatment plan and prioritize hematology-oncology management. [21] |
| CD5 positivity with cyclin D1 positivity | Raises mantle cell lymphoma in the differential rather than DLBCL. [22] | Correlate with morphology and evaluate for the characteristic BCL1-IGH rearrangement. [22] |

## Stage promptly and use biology to identify patients needing early escalation

Baseline disease extent and molecular risk determine urgency, treatment intensity discussions, and relapse planning.

Complete baseline staging with FDG-PET/CT and document extranodal disease, bulky disease, performance status, serum LDH, and International Prognostic Index. In POLARIX, bulky disease was defined as one or more lesions at least 7.5 cm in greatest diameter, and treatment randomization was stratified by IPI 2 versus 3-5 and bulk. [4]

Treat MYC, BCL2, and BCL6 rearrangement assessment as a standard component of DLBCL workup. Double-hit and triple-hit lymphomas, defined by MYC rearrangement with BCL2, BCL6, or both rearrangements, have poor outcomes with standard chemotherapy and warrant early discussion at a center experienced in aggressive B-cell lymphoma. [11][21]

Assess for central nervous system involvement at baseline when neurologic symptoms or signs are present, and recognize CNS involvement as a high-risk feature. CNS relapse has been reported in approximately 5% of DLBCL and is associated with poor outcomes; patients with CNS involvement or double-/triple-hit features may require an altered treatment approach rather than routine management. [19][24]
- Record pretreatment cardiac function before anthracycline-containing therapy because both R-CHOP and pola-R-CHP include doxorubicin 50 mg/m² on day 1 of each of the first six cycles. [4]
- Document baseline blood counts before treatment and before cellular or T-cell-engaging therapy because prolonged cytopenias, infection, and bleeding risks can complicate later CAR T-cell or bispecific-antibody treatment. [18][20]

*Baseline features with immediate implications for treatment planning. [4][11][19][21][24]*

| Feature | Clinical implication | Immediate planning step |
| --- | --- | --- |
| IPI 2-5 | Matches the risk population enrolled in POLARIX. [4] | Discuss pola-R-CHP as a frontline option when otherwise appropriate. [4] |
| Bulky lesion ≥7.5 cm | High tumor burden variable used in frontline trial stratification. [4] | Document on baseline imaging for response assessment and treatment planning. [4] |
| MYC with BCL2 and/or BCL6 rearrangement | High-risk double-hit/triple-hit lymphoma with poor outcome after standard chemotherapy. [21] | Complete expert pathology review and expedite specialist treatment planning. [11][21] |
| Neurologic findings or documented CNS involvement | CNS disease is a high-risk feature; CNS relapse has poor outcomes. [19][24] | Perform CNS-directed diagnostic assessment and do not rely on routine systemic treatment planning alone. [19] |

## Use curative-intent anthracycline-based immunochemotherapy for appropriate newly diagnosed disease

Frontline treatment selection should be finalized only after pathology, staging, cardiac assessment, and risk documentation.

R-CHOP remains a curative-intent chemoimmunotherapy backbone for DLBCL. In the POLARIX trial, the comparator regimen comprised rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² with a 2-mg maximum, and prednisone 100 mg orally once daily on days 1-5 for six 21-day cycles, followed by two further rituximab-containing cycles. [4]

For previously untreated DLBCL with IPI 2-5, consider pola-R-CHP: polatuzumab vedotin 1.8 mg/kg intravenously on day 1 plus rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², and prednisone 100 mg orally on days 1-5, every 21 days for six cycles, followed by two additional rituximab-containing cycles. Polatuzumab replaces vincristine in this regimen. [4]

POLARIX showed greater persistence of remission with pola-R-CHP than R-CHOP among patients achieving complete response, with a hazard ratio for relapse or death of 0.70 (95% CI, 0.50-0.98); overall survival did not differ significantly. Present this as a disease-control benefit rather than a demonstrated survival advantage. [4]

Do not postpone first-line therapy while waiting for every molecular result when the patient has clinically aggressive disease, but ensure MYC, BCL2, and BCL6 rearrangement testing is in process before the treatment course is fixed. Patients with double-hit or triple-hit genetics have poor outcomes with standard chemotherapy and should be managed with early high-risk lymphoma input. [11][21]
- Use prednisone 100 mg once daily on days 1-5 in both POLARIX treatment arms. [4]
- Avoid coadministration of vincristine with pola-R-CHP; the regimen was designed with placebo-matched vincristine in the R-CHOP arm and polatuzumab in the experimental arm. [4]
- Reassess with response imaging after planned therapy; persistent or progressive FDG-avid disease should prompt biopsy when feasible before committing to salvage or cellular therapy. This avoids treating inflammatory uptake or an alternative lymphoma process as relapsed DLBCL.

*Frontline POLARIX regimen components and comparative outcome. [4]*

| Regimen | First six 21-day cycles | Cycles 7-8 | Key trial result |
| --- | --- | --- | --- |
| Pola-R-CHP | Polatuzumab vedotin 1.8 mg/kg IV, rituximab 375 mg/m² IV, cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV on day 1; prednisone 100 mg orally days 1-5. [4] | Rituximab-containing treatment continued. [4] | More durable remission among complete responders; no significant overall-survival difference versus R-CHOP. [4] |
| R-CHOP | Rituximab 375 mg/m² IV, cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1; prednisone 100 mg orally days 1-5. [4] | Rituximab-containing treatment continued. [4] | Comparator regimen in POLARIX. [4] |

## Sequence therapy by timing of failure, CAR T-cell eligibility, and need for rapid disease control

Relapse within 12 months and later relapse represent different therapeutic decision points.

At progression, obtain biopsy of an accessible active lesion when clinically feasible, particularly after a long remission, when imaging is discordant, or when transformation or an alternative process is plausible. Then classify the event by timing: refractory disease or relapse within 12 months of first-line treatment supports referral for second-line CAR T-cell therapy assessment; axicabtagene ciloleucel and lisocabtagene maraleucel are used in this setting. [21]

Refer early to a CAR T-cell center rather than exhausting multiple ineffective systemic regimens. Bridging chemoimmunotherapy or radiation therapy may be used to reduce tumor burden before CAR T-cell infusion, but treatment selection must preserve fitness for lymphodepletion and cellular therapy. [21]

For relapsed or refractory DLBCL after at least two systemic lines, CD20×CD3 bispecific antibodies offer an important option for patients who previously received CAR T-cell therapy or are ineligible for or unable to receive it. Glofitamab is administered intravenously for a fixed duration of up to 12 21-day cycles, totaling 13 doses over 36 weeks, unless progression or unacceptable toxicity occurs. [19]

Epcoritamab is a subcutaneous, indefinite-duration treatment schedule: weekly for 3 months, then every 2 weeks for 6 months, with 24 doses over the initial 36 weeks; subsequent administration continues according to the treatment schedule until progression or unacceptable toxicity. Consider treatment logistics, expected adherence, cytopenias, infection risk, and local capability for cytokine-release syndrome management when choosing between a fixed-duration intravenous and ongoing subcutaneous strategy. [19][20]
- CAR T-cell therapy can cause cytokine-release syndrome within days of infusion, typically with fever, hypotension, and hypoxia; reported CRS incidence ranges from 42% to 93%, with grade 3 or higher events in about 8%. [18]
- Monitor for immune effector cell-associated neurotoxicity syndrome after CAR T-cell therapy: confusion, aphasia, seizures, and rarely cerebral edema are reported; ICANS occurs in 14% to 40%, with grade 3 or higher events in approximately 11%. [18]
- Plan longitudinal surveillance for cytopenias, infection, and B-cell aplasia after CAR T-cell therapy or bispecific-antibody treatment; consider immunoglobulin replacement when clinically appropriate. [20]
- During epcoritamab initiation, prophylactic dexamethasone and hydration reduced cytokine-release syndrome rates and severity in reported long-term experience. [9]

*Relapsed or refractory DLBCL treatment-selection framework. [18][19][20][21]*

| Clinical setting | Preferred next action | Key operational risk |
| --- | --- | --- |
| Primary refractory disease or relapse within 12 months of first-line therapy | Urgently evaluate for second-line CAR T-cell therapy, including axicabtagene ciloleucel or lisocabtagene maraleucel. [21] | Disease control may require bridging therapy before infusion. [21] |
| High disease burden while awaiting CAR T-cell manufacturing or infusion | Use individualized bridging chemoimmunotherapy or radiation therapy to lower tumor burden. [21] | Avoid clinical deterioration that prevents lymphodepletion or infusion. [21] |
| At least two prior systemic lines; post-CAR T or not eligible for CAR T | Consider glofitamab, a fixed-duration IV CD20×CD3 bispecific regimen. [19] | Monitor for T-cell-engaging therapy toxicities and infectious complications. [19][20] |
| At least two prior systemic lines; need for subcutaneous ambulatory option | Consider epcoritamab with weekly then every-2-week dosing. [19] | Use CRS mitigation and monitor cytopenias and infection risk. [9][19][20] |

## Monitor response and immunotherapy complications with predefined escalation triggers

Post-treatment surveillance should focus on confirming relapse and detecting treatment-related immune and hematologic toxicity.

After first-line immunochemotherapy, interpret residual or recurrent radiographic abnormalities in the context of clinical trajectory and obtain tissue confirmation when feasible before declaring relapse. This is particularly important when a new lesion emerges after a prolonged remission or when prior indolent lymphoma creates the possibility of recurrent low-grade disease rather than recurrent DLBCL.

Following CAR T-cell therapy, evaluate fever, hypotension, or hypoxia immediately for cytokine-release syndrome and assess new confusion, aphasia, or seizure for ICANS. Severe CRS and neurotoxicity occur in a clinically meaningful minority of recipients, so treatment should be delivered with rapid access to experienced toxicity management and inpatient escalation. [18]

Monitor complete blood counts and infectious complications beyond the immediate treatment period after CAR T-cell or bispecific-antibody therapy. Prolonged neutropenia, anemia, thrombocytopenia, B-cell aplasia, and infection risk may persist, and hypogammaglobulinemia may justify immunoglobulin replacement in selected patients. [18][20]
- Escalate urgently for fever with hypotension or hypoxia after CAR T-cell infusion because this pattern is characteristic of cytokine-release syndrome. [18]
- Escalate urgently for altered mental status, aphasia, convulsions, or suspected cerebral edema after CAR T-cell infusion because these may represent ICANS. [18]
- Track cytopenias and infections during the first six months after CAR T-cell therapy, when prolonged hematologic toxicity is common. [18]

*Toxicity patterns requiring active surveillance after T-cell-engaging therapy. [18][20]*

| Therapy-associated complication | Typical presentation or consequence | Monitoring response |
| --- | --- | --- |
| Cytokine-release syndrome | Within days after CAR T-cell infusion: fever, hypotension, and hypoxia; grade 3 or higher events occur in about 8%. [18] | Assess vital signs promptly and escalate to an experienced cellular-therapy toxicity team. [18] |
| ICANS | Confusion, aphasia, seizures, and rarely cerebral edema; grade 3 or higher events occur in approximately 11%. [18] | Perform urgent neurologic assessment and manage through the cellular-therapy program. [18] |
| Prolonged cytopenias and B-cell aplasia | Neutropenia, anemia, thrombocytopenia, bleeding, infection, and possible hypogammaglobulinemia. [18][20] | Follow blood counts and infections longitudinally; consider immunoglobulin replacement when appropriate. [20] |

## References
1. Venetoclax–Rituximab in Relapsed or Refractory Chronic ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa1713976
2. Rituximab plus Lenalidomide in Advanced Untreated ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa1805104
3. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa1802917
4. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2115304
5. Supplementary appendix — www.thelancet.com — https://www.thelancet.com/cms/10.1016/S1470-2045(19)30091-9/attachment/3873ff4c-9ffa-49cf-acdb-c21c1c918892/mmc1.pdf
6. A British Society of Haematology Guideline — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.19064
7. Publications - 2015 - Hematological Oncology — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/hon.2229
8. American Journal of Hematology | Blood Research Journal — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.23372
9. American Journal of Hematology | Blood Research Journal | Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/ajh.27491
10. Article B-cell lymphomas with concurrent MYC and BCL2 ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0893395222034834
11. Research Article Diffuse Large B-Cell Lymphoma/High ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0893395225000067
12. Aggressive B-cell lymphomas: how many categories do we ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0893395222029970
13. Primary central nervous system diffuse large B-cell ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0344033816306264
14. The Image Biomarker Standardization Initiative: Standardized                     Quantitative Radiomics for High-Throughput Image-based                     Phenotyping | Radiology — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/radiol.2020191145
15. Imaging Primer on Chimeric Antigen Receptor T-Cell ... — pubs.rsna.org — https://pubs.rsna.org/doi/pdf/10.1148/rg.210065
16. Breast Implant–associated Anaplastic Large Cell Lymphoma — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/rg.2020190198
17. Radiomics: Images Are More than Pictures, They Are Data — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/radiol.2015151169
18. Bispecific Antibodies Versus Chimeric Antigen Receptor T ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12853145
19. Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12384478
20. Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11764151
21. CAR-T Cell Therapy in Large B Cell Lymphoma — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10631715
22. B Cell Lymphoma Cell - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/b-cell-lymphoma-cell
23. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0923753419471846
24. E‐POSTERS - 2021 - Hematological Oncology — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/hon.2880

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.